Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 57.18 0.97% 0.55
ONCE closed up 0.97 percent on Thursday, September 20, 2018, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ONCE trend table...

Date Alert Name Type % Chg
Sep 20 Death Cross Bearish 0.00%
Sep 20 NR7 Range Contraction 0.00%
Sep 20 Lower Bollinger Band Walk Weakness 0.00%
Sep 20 Inside Day Range Contraction 0.00%
Sep 20 Lower Bollinger Band Touch Weakness 0.00%
Sep 20 Oversold Stochastic Weakness 0.00%
Sep 19 Lower Bollinger Band Walk Weakness 0.97%
Sep 19 Below Lower BB Weakness 0.97%
Sep 19 Lower Bollinger Band Touch Weakness 0.97%
Sep 19 Oversold Stochastic Weakness 0.97%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 96.59
52 Week Low 41.06
Average Volume 685,120
200-Day Moving Average 67.0471
50-Day Moving Average 67.0104
20-Day Moving Average 60.245
10-Day Moving Average 58.798
Average True Range 2.5287
ADX 35.56
+DI 8.9875
-DI 23.979
Chandelier Exit (Long, 3 ATRs ) 55.7839
Chandelier Exit (Short, 3 ATRs ) 63.8961
Upper Bollinger Band 64.0129
Lower Bollinger Band 56.4771
Percent B (%b) 0.09
BandWidth 12.50859
MACD Line -2.4026
MACD Signal Line -2.4997
MACD Histogram 0.0971
Fundamentals Value
Market Cap 1.79 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -8.95
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.39
Resistance 3 (R3) 59.39 58.65 59.02
Resistance 2 (R2) 58.65 58.08 58.65 58.90
Resistance 1 (R1) 57.91 57.74 58.28 57.92 58.78
Pivot Point 57.17 57.17 57.36 57.17 57.17
Support 1 (S1) 56.44 56.61 56.81 56.44 55.58
Support 2 (S2) 55.70 56.26 55.70 55.46
Support 3 (S3) 54.96 55.70 55.34
Support 4 (S4) 54.97